Prof.Dr.LEVENT KABASAKAL | Ac-225-PSMA for Castration Resistant Metastatic Prostate Cancer
Prof.Dr.LEVENT KABASAKAL | Ac-225-PSMA for Castration Resistant Metastatic Prostate Cancer
![Clinical Experience with [225Ac]Ac-PSMA Treatment in Patients with [177Lu]Lu-PSMA–Refractory Metastatic Castration-Resistant Prostate Cancer | Journal of Nuclear Medicine](https://jnm.snmjournals.org/content/jnumed/early/2023/08/23/jnumed.123.265546/F1.large.jpg "Clinical Experience with [225Ac]Ac-PSMA Treatment in Patients with [177Lu]Lu-PSMA–Refractory Metastatic Castration-Resistant Prostate Cancer | Journal of Nuclear Medicine")
Clinical Experience with [225Ac]Ac-PSMA Treatment in Patients with [177Lu]Lu-PSMA–Refractory Metastatic Castration-Resistant Prostate Cancer | Journal of Nuclear Medicine
Efficacy and safety of 225Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant Prostate Cancer patients
225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study.
Synthesis of 225Ac-PSMA-617 for Preclinical Use | Bentham Science
Safety and Activity of Alpha-Emitting Ac-225-PSMA-617 Radioligand Therapy in mCRPC That Has Progressed After Lu-177-PSMA, Journal Club – Christopher Wallis & Zachary Klaassen
225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer | Journal of Nuclear Medicine
Efficacy and safety of Ac-225-PSMA-617 TAT in Prostate Cancer - Oncidium Foundation
225Actinium-labeled prostate-specific membrane antigen targeting peptide induces complete response in a metastatic prostate cancer patient - Omer Aras, Stefan Harmsen, Richard Ting, Haluk B Sayman, 2021
Lu-177 PSMA therapy vs Ac-225 PSMA therapy
Ac-225 PSMA therapy
⁶⁸Ga-PSMA-11 PET/CT scans of a representative patient with mCRPC after... | Download Scientific Diagram
![Cancers | Free Full-Text | [225Ac]Ac-SibuDAB for Targeted Alpha Therapy of Prostate Cancer: Preclinical Evaluation and Comparison with [225Ac]Ac-PSMA -617](https://pub.mdpi-res.com/cancers/cancers-14-05651/article_deploy/html/images/cancers-14-05651-ag.png?1669355153 "Cancers | Free Full-Text | [225Ac]Ac-SibuDAB for Targeted Alpha Therapy of Prostate Cancer: Preclinical Evaluation and Comparison with [225Ac]Ac-PSMA -617")
Cancers | Free Full-Text | [225Ac]Ac-SibuDAB for Targeted Alpha Therapy of Prostate Cancer: Preclinical Evaluation and Comparison with [225Ac]Ac-PSMA -617
Novel radioligand therapy proven superior for | EurekAlert!
Response to 225Ac-PSMA-I&T after failure of long-term 177Lu-PSMA RLT in mCRPC | European Journal of Nuclear Medicine and Molecular Imaging
PSMA Lu-177 x Ac-225 - Oncidium Foundation
225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study | European Journal of Nuclear Medicine and Molecular Imaging
Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA - European Urology
![Figure 2, [Patient selection for targeted radionuclide...]. - Prostate Cancer - NCBI Bookshelf](https://www.ncbi.nlm.nih.gov/books/NBK571320/bin/chapter6_f2.jpg "Figure 2, [Patient selection for targeted radionuclide...]. - Prostate Cancer - NCBI Bookshelf")
Figure 2, [Patient selection for targeted radionuclide...]. - Prostate Cancer - NCBI Bookshelf
![Clinical Experience with [225Ac]Ac-PSMA Treatment in Patients with [177Lu]Lu-PSMA–Refractory Metastatic Castration-Resistant Prostate Cancer | Journal of Nuclear Medicine](https://jnm.snmjournals.org/content/jnumed/early/2023/08/23/jnumed.123.265546/F6.large.jpg "Clinical Experience with [225Ac]Ac-PSMA Treatment in Patients with [177Lu]Lu-PSMA–Refractory Metastatic Castration-Resistant Prostate Cancer | Journal of Nuclear Medicine")
Clinical Experience with [225Ac]Ac-PSMA Treatment in Patients with [177Lu]Lu-PSMA–Refractory Metastatic Castration-Resistant Prostate Cancer | Journal of Nuclear Medicine
A) 68 Ga-PSMA-11 PET/CT scan of patient with pretherapeutic tumor... | Download Scientific Diagram
Lu-177 PSMA therapy vs Ac-225 PSMA therapy
First clinical results for PSMA TAT using Ac-225-PSMA-I&T in advanced mCRPC patients - Oncidium Foundation
![Structural formula of [ 225 Ac]Ac-PSMA-I&T, with DOTAGA as a chelator.... | Download Scientific Diagram](https://www.researchgate.net/publication/351584466/figure/fig1/AS:1024889205047296@1621364036254/Structural-formula-of-225-AcAc-PSMA-I-T-with-DOTAGA-as-a-chelator-Structural.png "Structural formula of [ 225 Ac]Ac-PSMA-I&T, with DOTAGA as a chelator.... | Download Scientific Diagram")